 | | | | Hours into his new job, California Governor Gavin Newsom signed an executive order on Monday that could dramatically reshape the way prescription drugs are paid for and acquired in the most populous U.S. state. | | | | | | The highly contagious foot and mouth disease, which poses a threat to the livestock industry, has been detected in a northern district of South Africa's Limpopo province, the country said on Tuesday. | | | | | | A leading geneticist who ran the conference where a Chinese scientist said he had made the world's first "gene-edited" babies condemned him on Monday for potentially jeopardizing lives and having no biology training. | | | | | | A California jury on Monday heard opening statements in the latest trial over allegations that Johnson & Johnson's talc-based products, including the company's baby powder, were contaminated with asbestos and cause cancer. | | | | | | (Reuters Health) - The growing popularity of e-cigarettes among U.S. youth may be associated with increased use of potentially dangerous flavored tobacco products, a new study suggests. | | | | | | (Reuters Health) - Much of the variation in smoking rates across American cities can be explained by the higher density of tobacco retailers in poor, nonwhite neighborhoods, a study of the 500 largest U.S. cities suggests. | | | | | | (Reuters Health) - The risk of heart disease and premature death may be higher for people who experience sudden, unpredictable income drops in early adulthood, a new study suggests. | | | | | | (Reuters Health) - Heart attack survivors who step up their exercise efforts may live longer than those who remain inactive, a Swedish study suggests. | | | | | | Amgen Inc on Monday lost its bid at the U.S. Supreme Court to overturn a ruling that kept the Regeneron Pharmaceuticals Inc and Sanofi SA cholesterol-lowering drug Praluent on the market, but the patent dispute among the rival drugmakers will continue in another trial. | | | | | | U.S. Supreme Court justices on Monday appeared sympathetic to Merck & Co in its bid to fend off hundreds of lawsuits accusing the company of failing to adequately warn patients of the risks of thigh bone fractures associated with its osteoporosis drug Fosamax. | | | | | | Sanofi will pay Regeneron some $462 million in a revision of their deal in immuno-oncology, a growing sector in healthcare research which aims to help the body's own immune system fight cancer. | | | | | |
